Non-Small Cell Lung Cancer
Advertisement
Dr. Liu unpacks key questions in the field, and the research that could address them.
Certain surgical procedures and margins were more frequent in patients who had suture-line recurrences.
The long-term follow-up data shows that PFS remains unreached in the subgroup of Asian patients in the CROWN study.
Researchers evaluated if there was a link between pretreatment systemic immune inflammation index levels and outcomes.
Clinicians hypothesize that the genetic mutation, known as RUFY1-RET fusion, caused resistance to lorlatinib.
Researchers evaluated if demographics, clinical characteristics, and outcomes varied between those with KRAS G12C and G12D.
The therapy is currently under evaluation in phase 1 and phase 2 trials.
A distributed clinical trial is analyzing diet and exercise patterns in young people with lung cancer.
The Prescription Drug User Fee Act action date is expected in the third quarter of 2025.
Dr. Liu unpacks the trial results, the recent approval, and the unique biomarker testing considerations for NRG1 fusions.
It is the "first and only neoadjuvant-only immuno-oncology therapy" to show a significant OS benefit in this setting.
Christopher Seder, MD, discusses the database and how it can be used for research, quality improvement, and risk ...
The 12-member board will guide the guide the patient-driven organization’s research and strategic priorities.
The study is comparing ivonescimab plus platinum-based chemotherapy with tislelizumab plus platinum-based chemotherapy.
The bispecific antibody, which recently received FDA accelerated approval, showed a response rate of 29% in NSCLC.
Dr. Merritt shares new thoracic surgery research insights for patient selection in sublobar resection for early-stage NSCLC.
The study aims to confirm safety and efficacy findings from the phase 2 QUILT 3.055 trial.
The study is evaluating a prophylactic dermatologic regimen in patients receiving amivantamab plus lazertinib.
The CHMP positive opinion is supported by results from the phase 3 PALOMA-3 study.
Dr. Seder discusses the real-world study he presented at STS 2025, which addressed key questions about long-term outcomes.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
Connect
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.